MedElevator
Войти в исследования Irish journal of medical science · 2003
Cost-effectiveness of spironolactone in patients with severe heart failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tilson L, McGowan B, Ryan M, Barry M
Аннотация
BACKGROUND: Management of heart failure is estimated to consume between 1% and 2% of total healthcare resources with hospital admissions accounting for up to 70% of this. The ability of the aldosterone antagonist spironolactone to reduce hospital admission rates by 35% would be expected to prove cost-effective.
AIM: To determine the cost-effectiveness of spironolactone when added to standard therapy in patients with severe chronic heart failure.
METHODS: A Markov model of chronic heart failure was constructed using Treeage software. Irish cost data were incorporated into the model.
RESULTS: The incremental cost-effectiveness ratio (ICER) for spironolactone therapy was Euro 466 per life year gained (LYG). Sensitivity analysis demonstrated an ICER range of Euro 75 to Euro 1,136 per LYG.
CONCLUSION: This economic evaluation suggests that the addition of spironolactone to standard therapy for patients with severe chronic heart failure is not only safe and effective, but is highly cost-effective in the Irish healthcare setting.
AIM: To determine the cost-effectiveness of spironolactone when added to standard therapy in patients with severe chronic heart failure.
METHODS: A Markov model of chronic heart failure was constructed using Treeage software. Irish cost data were incorporated into the model.
RESULTS: The incremental cost-effectiveness ratio (ICER) for spironolactone therapy was Euro 466 per life year gained (LYG). Sensitivity analysis demonstrated an ICER range of Euro 75 to Euro 1,136 per LYG.
CONCLUSION: This economic evaluation suggests that the addition of spironolactone to standard therapy for patients with severe chronic heart failure is not only safe and effective, but is highly cost-effective in the Irish healthcare setting.